Education and Training
A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
This study is designed to evaluate the preliminary anti-tumor activity and tolerability of PF-03084014 when administered as a single agent in the treatment of patients with advanced triple receptor-negative breast cancer (mTNBC) harboring genomic alterations in Notch receptors (NA+), and in a smaller subset of mTNBC patients whose tumor tests negative for genomic alterations in Notch receptors (NA-)
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: PF-03084014
- drug: PF-03084014
- drug: PF-03084014
Eligibility
Inclusion Criteria:
- Histological or cytological diagnosis of triple negative breast cancer (TNBC) with
evidence of a) metastatic or b) locally recurrent advanced disease that is not
amenable to resection or radiotherapy with curative intent.
- Availability of an original diagnostic tumor tissue or the most recent metastatic
tumor biopsies (archival biopsy or de novo biopsy) and a peripheral blood sample for
Notch receptors genomic profiling
Exclusion Criteria:
- Known brain metastases.
- Prior treatment with gamma secretase inhibitor or other Notch signaling inhibitor.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Female
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting